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Introduction: The purposes of this study are to investigate the asso-
ciation between cigarette smoking and clinicopathological characteris-
tics of patients with non-small cell lung cancer (NSCLC) and to
evaluate its significance as a predictor of recurrence after resection.
Methods: A total of 2295 consecutive patients with NSCLC under-
went complete resection with systematic node dissection between
August 1992 and December 2006 at the National Cancer Center
Hospital East.
Results: A statistically significant difference in the 5-year overall
survival rate was observed between never and ever smokers in
patients with stage I (92% and 76%, respectively, p  0.001)
NSCLC, whereas no difference was observed in stage II (57% and
52%, respectively, p  0.739) and stage III (30% and 33%, respec-
tively, p  0.897). In patients with stage I NSCLC, 5-year recur-
rence-free proportions (RFPs) for never and ever smokers were 89%
and 80%, respectively (p  0.001). In contrast, the 5-year RFPs for
never smokers were lower than those for ever smokers in stage II
(44% and 60%, respectively, p  0.049) and stage III (17% and
31%, respectively, p  0.004). In stage I patients, significant
difference in 5-year RFP was observed between never and ever
smokers (89% and 83%, respectively) in patients with adenocarci-
noma, but not in patients with nonadenocarcinoma (82% and 76%,
respectively).
Conclusions: Smoking history showed different impact on postop-
erative recurrence in patients with NSCLC between stage I and
stages II and III, and depending on histology in stage I patients.
Disease stages should be considered while evaluating smoking
history as a predictor of recurrence.
Key Words: Non-small cell lung cancer, Adenocarcinoma, Ciga-
rette smoking, Thoracic surgery, Recurrence.
(J Thorac Oncol. 2011;6: 735–742)
Cigarette smoking is a well-known habitual risk factor forlung cancer1 and is strongly associated with many other
factors, such as low socioeconomic status,2 poor nutrition,3
comorbidity,4 and impaired immune function.5 These smok-
ing-associated factors may contribute to poor survival of
cigarette smokers after lung cancer resection. Although sev-
eral studies have reported that cigarette smoking has a neg-
ative effect on lung cancer patient prognoses,6–10 whether
cigarette smoking affects the biological behavior of lung
cancer and whether it can be a predictor of recurrence after
resection remain unclear.
The purposes of this study are to investigate the asso-
ciation between cigarette smoking and clinicopathological
characteristics of patients with non-small cell lung cancer
(NSCLC) and to evaluate the significance of cigarette smok-
ing as a predictor of recurrence after resection. To offset the
prognostic impact of comorbidities associated with cigarette
smoking, we investigated recurrence-free proportion (RFP) in
addition to overall survival rate.
PATIENTS AND METHODS
Patients
Two thousand three hundred sixty-seven consecutive
patients with NSCLC underwent complete resection with
lobectomy or greater and systematic node dissection between
August 1992 and December 2006 at our institution. Complete
resection was defined as cancer-free surgical margins ob-
served in both gross and histological examinations. Of these
2367 patients, 72 patients who underwent preoperative che-
motherapy or radiation therapy, or both (n  43) or had
low-grade pulmonary malignancies (n  29) including car-
cinoids, mucoepidermoid carcinomas, and adenoid cystic
carcinomas were excluded from this study. The remaining
2295 patients were the subjects of this study.
Pathological Evaluations
Disease stages were diagnosed based on the tumor,
node, metastasis (TNM) classification of the International
Union Against Cancer, seventh edition.11 Histological type of
adenocarcinomas was determined according to the World
Health Organization’s classification.12 Adenocarcinomas
were histologically graded as well, moderately, or poorly
differentiated carcinomas according to the degree of struc-
tural and cytological atypia. Bronchioloalveolar carcinoma
(BAC) was categorized as a well-differentiated component,
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acinar, and papillary adenocarcinomas as moderately differ-
entiated components, and solid carcinoma with mucin pro-
duction without any clear gland formation as a poorly differ-
entiated component. When more than one differentiation
component was identified in a tumor, the differentiation of
the most predominant component was registered as its histo-
logical differentiation. Intratumoral vascular invasion (IVI)
and visceral pleural invasion (VPI) were evaluated by hema-
toxylin and eosin and elastin (Victoria blue-van Gieson)
staining. VPI was classified as defined in the TNM Classifi-
cation, seventh edition.11
Patient Follow-Up
We examined patients at 3-month intervals for the first
2 years and at 6-month intervals thereafter on an outpatient
basis. The follow-up evaluation included physical examina-
tion, chest radiography, and blood examination including that
of pertinent tumor markers. Further evaluations, including
computed tomography scans of the chest and abdomen, brain
magnetic resonance imaging, and bone scintigraphy, were
performed on the detection of any symptoms or signs of
recurrence. Since 2004, integrated positron emission tomog-
raphy and computed tomography have also been performed
when appropriate.
We diagnosed recurrence on the basis of findings of
physical examination and diagnostic imaging and confirmed
the diagnosis histologically when clinically feasible. Date of
recurrence was defined as the date of cytohistological proof.
Nevertheless, in cases diagnosed on the basis of clinicoradio-
logical findings, date of recurrence was defined as the date of
identification by a physician.
Clinicopathological Information
We prospectively collected information on cigarette
smoking status using the hospital outpatient clinic question-
naire, which was completed by patients at their first visit. We
asked patients to record the age at which they started smok-
ing, duration of smoking, and average daily cigarette con-
sumption. No environmental cigarette smoke exposure data
were collected. Smoking extent was quantified in pack-years
(PY), with 1 PY equivalent to 20 cigarettes on average per
day for 1 year. Before admission, all patients were required to
stop smoking.
We reviewed each patient’s medical record to obtain
clinicopathological information, which included age (dichot-
omized at the median age of 65 years), gender, smoking
extent (dichotomized at the median value of 43 PY in ever
smokers), diameter of the tumor on resected specimens (3
or 3 cm), tumor histology (adenocarcinoma or nonadeno-
carcinoma), tumor location (upper/middle lobe or lower
lobe), tumor laterality (right or left), and pathological stage
(stage I, II, or III based on the TNM classification, seventh
edition).11
Statistical Analysis
Differences in categorical outcomes were evaluated by
the 2 test. Continuous variables were compared using the t
test. The length of overall survival rate was calculated in
months from the date of resection to the date of death because
of any cause or of last follow-up. The length of RFP was
calculated in months from the date of resection to the date of
the first recurrence or last follow-up. To calculate RFP,
patients who died without recurrence or who were known to
be recurrence free at the date of last contact were censored. In
univariate analyses, all cumulative survival rates or RFPs
were estimated using the Kaplan–Meier method, and differ-
ences in variables were evaluated using the log-rank test.
Multivariate analyses were performed using the Cox propor-
tional hazards regression model. All p values reported were
two sided, and the significance level was set at less than 0.05.
Analyses were performed using the statistical software SPSS
version 11.0 (Dr. SPSS II for Windows, SPSS Inc., Chicago,
IL) and GraphPad Prism (Prism for Windows, version 5.02,
GraphPad Software Inc., La Jolla, CA).
Data collection and analyses were approved, and the
need to obtain written informed consent from each patient
was waived by the institutional review board in April 2010.
RESULTS
Smoking Extent and Clinicopathological
Factors
The median follow-up period was 53 months (range,
1–163 months). The details of patient characteristics and
smoking extent are shown in Table 1. Smoking extent was
TABLE 1. Patient Characteristics and Smoking Extent
Characteristics
No. of
Patients (%)
Smoking
Extent
(PY  SE) pa
Overall 2295 31.8  0.7
Age, yr (mean, 64.8;
range, 20–89)
65 1148 (50) 28.9  0.9
65 1147 (50) 34.6  1.0 0.001
Gender
Women 840 (37) 6.5  0.5
Men 1455 (63) 46.4  0.8 0.001
Tumor size (cm)
3.0 1218 (53) 26.5  0.9
3.0 1077 (47) 37.7  1.0 0.001
Tumor location
Upper/middle lobe 1448 (63) 31.4  0.8
Lower lobe 847 (37) 32.3  1.1 0.528
Tumor laterality
Right 1383 (60) 32.2  0.9
Left 912 (40) 31.2  1.0 0.463
Histological type
Adenocarcinoma 1585 (69) 22.4  0.7
Nonadenocarcinoma 710 (31) 52.8  1.1 0.001
Stage
I 1357 (59) 26.9  0.8
II 488 (21) 39.9  1.4 0.001b
III 450 (20) 37.5  1.6 0.001b
aBy t test.
bCompared with stage I patients.
PY, pack-years; SE, standard error.
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greater in older patients than in younger patients. Smoking
was more common in male patients than in female patients.
Smoking extent in patients with larger tumor size, nonade-
nocarcinoma, and stage II or higher tumors was significantly
greater than those in patients with smaller tumor size, ade-
nocarcinoma, or stage I tumors.
Correlation between Smoking Extent, Overall
Survival Rates, and RFPs According to Stage
Patients were classified into the following three sub-
groups according to smoking extent: group 1, never smokers
(PY  0); group 2, 0  PY  43; and group 3, PY  43.
Figures 1A, B show overall survival and RFP curves of
patients stratified by smoking extent. Five-year overall sur-
vival rates of patients in groups 1 (PY 0), 2 (0 PY 43),
and 3 (PY  43) were 77.9%, 64.1%, and 57.0%, respec-
tively. Statistically significant differences in survival rate
were observed among each group, but the group 2 survival
curve was apparently closer to the group 3 curve than to the
group 1 curve. Five-year RFPs of patients in groups 1, 2, and
3 were 72.3%, 65.3%, and 65.3%, respectively. Statistically
significant differences in RFPs were observed between
groups 1 and 2 and between groups 1 and 3, whereas no
difference was observed between groups 2 and 3. Therefore,
patients in groups 2 and 3 were together defined as ever
smokers (PY  0; Figures 1C, D) and compared with never
smokers (PY  0) in the following analyses.
Figures 2A–C show the overall survival curves plotted
according to the smoking history of patients with NSCLC in
stages I, II, and III. A statistically significant difference in the
5-year overall survival rate was observed between never and
ever smokers in patients with stage I (92.3% and 76.1%,
Figure 2A) NSCLC, whereas no differences were observed in
patients with stage II (57.0% and 51.7%, Figure 2B) and stage
III (29.8% and 33.0%, Figure 2C) NSCLC.
Figures 2D–F show the RFP curves plotted according
to the smoking history of patients with NSCLC in stages I, II,
and III. In patients with stage I NSCLC, the 5-year RFP for
never smokers (88.7%) was significantly higher than that for
FIGURE 1. Overall survival and recurrence-free proportion (RFP) curves according to smoking status in the entire cohort. A,
Overall survival curves according to smoking extent. B, RFP curves according to smoking extent. C, Overall survival curves ac-
cording to smoking history. D, RFP curves according to smoking history. PY, pack-years.
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ever smokers (80.3%). In contrast, the 5-year RFPs for never
smokers were significantly lower than those for ever smokers
in patients with stage II (44.2% and 59.8%, Figure 2E) and
stage III (16.5% and 31.4%, Figure 2F) NSCLC.
Prognostic Impact of Cigarette Smoking on
Patients with Stage I NSCLC
Table 2 lists 5-year overall survival rates and RFPs ac-
cording to clinicopathological features of patients with stage I
NSCLC. Univariate analysis identified the following five statis-
tically significant prognostic and risk factors for recurrence: age,
gender, smoking history, histology, and stage. In multivariate
analysis, old age, ever smoking history, nonadenocarcinoma
histology, and stage IB were found to be statistically significant
independent unfavorable prognostic factors for overall survival
(Table 3). Statistically significant independent risk factors for
recurrence were ever smoking history and stage IB (Table 4).
Overall Survival Rates and RFPs for Never and
Ever Smokers with Stage I NSCLC Stratified by
Histological Type
Figures 3A, B show the overall survival curves of never
and ever smokers with stage I NSCLC stratified by histolog-
ical type. Among patients with stage I adenocarcinoma, 508
(49%) were never smokers and 523 (51%) were ever smok-
ers. Patients with stage I nonadenocarcinoma included 18
(6%) never smokers and 308 (94%) ever smokers. Statisti-
cally significant differences in 5-year overall survival rates
were observed between never and ever smokers in patients
with adenocarcinoma (92.4% and 81.8%, respectively, Figure
3A) and patients with nonadenocarcinoma (88.2% and 66.8%,
respectively, Figure 3B).
Figures 3C, D show the RFP curves of never and ever
smokers with stage I NSCLC stratified by histological type.
In patients with adenocarcinoma, a statistically significant
difference in 5-year RFP was observed between never and
ever smokers (88.9% and 82.7%, respectively, Figure 3C).
No statistically significant difference was observed in patients
with nonadenocarcinoma (82.2% and 76.3%, respectively,
Figure 3D).
Correlation between Smoking History and
Pathological Characteristics of Patients with
Stage I Adenocarcinoma
To determine the reason for the RFP being significantly
lower in ever smokers than in never smokers with stage I
adenocarcinoma, we investigated pathological characteristics
of patients with stage I adenocarcinoma. The correlation
between smoking history and pathological characteristics of
patients with stage I adenocarcinoma is shown in Table 5.
Ever smokers showed significantly more moderately or
poorly differentiated carcinomas and significantly more tu-
mors with IVI or VPI than never smokers.
DISCUSSION
Several studies have shown the significance of cigarette
smoking as a prognostic factor in patients with lung can-
FIGURE 2. Overall survival and recurrence-free proportion (RFP) curves according to smoking history in each stage. A, Over-
all survival curves of patients with stage I non-small cell lung cancer (NSCLC). B, Overall survival curves of patients with stage
II NSCLC. C, Overall survival curves of patients with stage III NSCLC. D, RFP curves of patients with stage I NSCLC. E, RFP
curves of patients with stage II NSCLC. F, RFP curves of patients with stage III NSCLC.
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cer.6–10 A recent Japanese population-based study6 reported
that ever smokers showed an unfavorable postoperative prog-
nosis compared with never smokers after complete NSCLC
resection. However, cigarette smoking is also a well-known
risk factor for severe pulmonary and cardiovascular diseases.4
Several studies8,13–15 found that approximately 20 to 40% of
smokers with lung cancer died without evidence of cancer
progression or recurrence. When patients who died of other
TABLE 2. Univariate Analyses of Prognostic Factors in Patients with Stage I NSCLC
Characteristics
No. of
Patients (%)
Overall
Survival Rate
at 5 yr (%)
Univariate
p Value
Recurrence-Free
Proportion at
5 yr (%)
Univariate
p Value
Overall 1357 82.5 82.8
Age (yr)
65 678 (50) 89.3 0.001a 86.3 0.002a
65 679 (50) 75.4 79.8
Gender
Women 583 (43) 89.8 0.001a 86.7 0.001a
Men 774 (57) 76.9 79.8
Smoking history
Never smoker 526 (39) 92.3 0.001a 87.7 0.001a
Ever smoker 831 (61) 76.1 78.3
Histological type
Adenocarcinoma 1031 (76) 87.1 0.001a 85.3 0.001a
Nonadenocarcinoma 326 (24) 68 74.8
Tumor location
Upper/middle lobe 918 (68) 83.3 0.619 82.8 0.951
Lower lobe 439 (32) 80.8 82.9
Tumor laterality
Right 846 (62) 84 0.083 84.5 0.053
Left 511 (38) 80 80
Stage
IA 805 (59) 90.6 0.001a 90.8 0.001a
IB 552 (41) 70.6 72.9
aIndicates significance.
NSCLC, non-small cell lung cancer.
TABLE 3. Multivariate Analyses of Prognostic Factors in Patients with Stage I NSCLC
Factors Unfavorable Favorable HR 95% CI p
Age (yr) 65 65 2.205 1.717–2.830 0.001a
Gender Men Women 1.149 0.832–1.587 0.399
Smoking history Ever smoker Never smoker 1.833 1.273–2.640 0.001a
Histological type Nonadenocarcinoma Adenocarcinoma 1.513 1.179–1.943 0.001a
Stage IB IA 2.436 1.918–3.092 0.001a
aIndicates significance.
HR, hazard ratio for death; CI, confidence interval; NSCLC, non-small cell lung cancer.
TABLE 4. Multivariate Analysis of Risk Factors for Recurrence in Patients with Stage I NSCLC
Factors Unfavorable Favorable HR 95% CI p
Age (yr) 65 65 1.205 0.928–1.564 0.161
Gender Men Women 1.038 0.732–1.472 0.835
Smoking history Ever smoker Never smoker 1.511 1.033–2.210 0.033a
Histological type Nonadenocarcinoma Adenocarcinoma 1.227 0.911–1.651 0.178
Stage IB IA 2.831 2.159–3.712 0.001a
aIndicates significance.
HR, hazard ratio for recurrence; CI, confidence interval; NSCLC, non-small cell lung cancer.
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diseases were excluded from the analysis, no significant
differences in lung cancer-specific survival rates were re-
ported to be observed between ever and never smokers.6
Whether cigarette smoking causes significant biological ag-
gressiveness in NSCLC, leading to more recurrence and
metastasis after resection, remains unclear. In this study, we
investigated the relationships between cigarette smoking and
clinicopathological characteristics and evaluated the prognos-
tic significance of cigarette smoking stratified by stage and
histology.
We found that postoperative NSCLC recurrences were
more frequent in ever smokers than in never smokers only in
stage I patients. Some recent studies also reported that ever
smoking history is an unfavorable prognostic factors in pa-
tients with stage I NSCLC.16,17 Based on the results of
multivariate analyses, ever smoking history, in addition to
disease stage, was considered an independent postoperative
predictor of recurrence in patients with stage I NSCLC.
Brundage et al.18 found 169 prognostic factors for patients
with NSCLC reported in 887 studies published between 1990
and 2001. Although most of these factors are not readily
observed in routine clinical practice, cigarette smoking his-
tory is the most commonly observed factor.
When we evaluated the prognostic significance of cig-
arette smoking stratified by histology among patients with
stage I NSCLC, significant differences in both overall sur-
vival and RFP were observed between never and ever smok-
ers in patients with adenocarcinoma. In patients with nonade-
nocarcinoma, however, significant differences were observed
in overall survival but not in RFP, which might be attribut-
able to the small number of stage I nonadenocarcinoma never
smokers. This result suggests that stage I adenocarcinomas in
ever smokers are more aggressive than those in never smok-
ers. Pathological characteristics of stage I adenocarcinomas
showed that tumors in ever smokers were significantly more
frequently poorly differentiated and were accompanied by
IVI or VPI than those in never smokers. These aggressive and
invasive characteristics might be the reason for ever smokers
FIGURE 3. Overall survival and recurrence-free proportion (RFP) curves according to smoking history in patients with stage I
non-small cell lung cancer. A, Overall survival curves of adenocarcinoma patients. B, Overall survival curves of nonadenocarci-
noma patients. C, RFP curves of adenocarcinoma patients. D, RFP curves of nonadenocarcinoma patients.
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developing more frequent recurrence than never smokers
among patients with stage I adenocarcinoma.
Cigarette smoke is known to contain numerous muta-
genic and carcinogenetic chemicals that may cause mutations
in tumor suppressor genes such as p53 and in oncogenes such
as K-ras.19–21 Suzuki et al.20 reported that tumors with p53
gene alterations showed high growth fraction percentages.
Tollerud et al.21 reported that cigarette smoking reduces local
airway immunity, and alveolar macrophages activated by
smoking suppress natural killer cell activity by producing
prostaglandins and oxygen radicals. These findings may ex-
plain the aggressive and invasive nature of stage I adenocar-
cinomas in ever smokers. In addition, many biomarkers have
been shown to be prognostic indicators of NSCLC, including
serum carcinoembryonic antigen, erbB2/Neu, BclII, promoter
hypermthylation of hMSH2 mismatch repair gene, and over-
expression of circulating c-met.22–26 In addition to patholog-
ical factors, correlation between these biomarkers and smok-
ing-related adenocarcinoma needs to be examined in the
future study.
Guo et al.16 and Bryant and Cerfolio17 reported no
significant statistical differences in overall survival rate be-
tween never smokers and ever smokers with stage II and
stage III NSCLC. In this study, significantly lower RFPs were
observed in never smokers than in ever smokers with stage II
and III NSCLC, although no significant differences were
observed in overall survival. These findings suggest that the
significance of smoking history in postoperative outcome
differs according to disease stage, and disease stages should
be considered while evaluating smoking history as a predictor
of recurrence after resection. However, we could not fully
explain the reason for the opposite results of the significance
of smoking history as a predictor of recurrence according to
stage. Bryant and Cerfolio17 reported that in patients with
NSCLC, never smokers had more poorly differentiated tu-
mors with higher maximum standardized uptake value of
18F-fluorodeoxyglucose on positron emission tomography
scans compared with ever smokers. The 18F-fluorodeoxyglu-
cose uptake correlates with the proliferative activity of tu-
mors and is reported to be an independent prognostic factor in
patients with lung cancer.27,28 Among patients with adeno-
carcinoma, the number of never smokers with BAC subtype
has recently increased in Japan, and BAC is often found at an
earlier stage and reported to be associated with a favorable
prognosis.29–31 Therefore, one possible explanation would be
that cancer histologic type distribution is different between
never and ever smokers and that the distribution is also
different between stages.
This retrospective study had several limitations in the
analyses. In particular, smoking status was reported by pa-
tients and was not confirmed biochemically, and therefore,
the data may be biased. Ethnic diversity was lacking in our
100% Japanese patient population. Second-hand tobacco
smoke is an established cause of lung cancer, but it was too
difficult to quantify this factor objectively and include it in
the analyses. Another limitation is that because nonadenocar-
cinoma never smokers were a mere fraction of the entire
cohort, we could not fully examine the correlation between
cigarette smoking and nonadenocarcinoma. Despite these
limitations, our results showed the stage in which cigarette
smoking had a prognostic impact after complete NSCLC
resection.
CONCLUSION
Smoking history showed different impact on postoper-
ative recurrence in NSCLC patients between stage I and
stages II and III, and depending on histology in stage I
patients. Disease stages and histology should be considered
while evaluating smoking history as a predictor of recurrence
after resection.
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